BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 19303143)

  • 1. Cellular accumulation and DNA platination of two new platinum(II) anticancer compounds based on anthracene derivatives as carrier ligands.
    Marqués-Gallego P; Kalayda GV; Jaehde U; Dulk Hd; Brouwer J; Reedijk J
    J Inorg Biochem; 2009 May; 103(5):791-6. PubMed ID: 19303143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of the leaving group for antitumor activity of new platinum(II) compounds containing anthracene derivatives as a carrier ligand.
    Marqués-Gallego P; Contaldi S; den Dulk H; Monari M; Brouwer J; Jaehde U; Kalayda GV; Reedijk J
    J Inorg Biochem; 2009 Dec; 103(12):1602-8. PubMed ID: 19783310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, crystal structure, studies in solution and cytotoxicity of two new fluorescent platinum(II) compounds containing anthracene derivatives as a carrier ligand.
    Marqués-Gallego P; den Dulk H; Brouwer J; Kooijman H; Spek AL; Roubeau O; Teat SJ; Reedijk J
    Inorg Chem; 2008 Dec; 47(23):11171-9. PubMed ID: 18975941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic activity and cellular processing in human ovarian carcinoma cell lines of a new platinum(II) compound containing a fluorescent substituted propylene diamine ligand.
    Marqués-Gallego P; den Dulk H; Brouwer J; Tanase S; Mutikainen I; Turpeinen U; Reedijk J
    Biochem Pharmacol; 2009 Aug; 78(4):365-73. PubMed ID: 19413998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
    Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
    Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.
    Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ
    Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
    Kelland LR; Sharp SY; O'Neill CF; Raynaud FI; Beale PJ; Judson IR
    J Inorg Biochem; 1999 Oct; 77(1-2):111-5. PubMed ID: 10626362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.
    Garmann D; Warnecke A; Kalayda GV; Kratz F; Jaehde U
    J Control Release; 2008 Oct; 131(2):100-6. PubMed ID: 18691617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three new asymmetric trans-amine(azole)dichloridoplatinum complexes that overcome cisplatin resistance and their reactions with 5'-GMP.
    Pantoja E; Gallipoli A; van Zutphen S; Komeda S; Reddy D; Jaganyi D; Lutz M; Tooke DM; Spek AL; Navarro-Ranninger C; Reedijk J
    J Inorg Biochem; 2006 Dec; 100(12):1955-64. PubMed ID: 17083978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA cleavage and antitumour activity of platinum(II) and copper(II) compounds derived from 4-methyl-2-N-(2-pyridylmethyl)aminophenol: spectroscopic, electrochemical and biological investigation.
    Roy S; Maheswari PU; Lutz M; Spek AL; den Dulk H; Barends S; van Wezel GP; Hartl F; Reedijk J
    Dalton Trans; 2009 Dec; (48):10846-60. PubMed ID: 20023915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New isomeric azine-bridged dinuclear platinum(II) complexes circumvent cross-resistance to cisplatin.
    Komeda S; Kalayda GV; Lutz M; Spek AL; Yamanaka Y; Sato T; Chikuma M; Reedijk J
    J Med Chem; 2003 Mar; 46(7):1210-9. PubMed ID: 12646031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and activity of a trinuclear platinum complex: [{trans-PtCl(NH3)2}2mu-{trans-Pt(3-hydroxypyridine)2(H2N(CH2)6NH2)2}]Cl4 in ovarian cancer cell lines.
    Tayyem H; Huq F; Yu JQ; Beale P; Fisher K
    ChemMedChem; 2008 Jan; 3(1):145-51. PubMed ID: 17963210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum(IV)-nitroxyl complexes as possible candidates to circumvent cisplatin resistance in RT112 bladder cancer cells.
    Cetraz M; Sen V; Schoch S; Streule K; Golubev V; Hartwig A; Köberle B
    Arch Toxicol; 2017 Feb; 91(2):785-797. PubMed ID: 27307157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells.
    Zisowsky J; Koegel S; Leyers S; Devarakonda K; Kassack MU; Osmak M; Jaehde U
    Biochem Pharmacol; 2007 Jan; 73(2):298-307. PubMed ID: 17097621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model platinum nucleobase and nucleoside complexes and antitumor activity: X-ray crystal structure of [PtIV(trans-1R,2R-diaminocyclohexane)trans-(acetate)2(9-ethylguanine)Cl]NO3.H2O.
    Ali MS; Khan SR; Ojima H; Guzman IY; Whitmire KH; Siddik ZH; Khokhar AR
    J Inorg Biochem; 2005 Mar; 99(3):795-804. PubMed ID: 15708801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of carrier ligand in platinum resistance in L1210 cells.
    Gibbons GR; Page JD; Mauldin SK; Husain I; Chaney SG
    Cancer Res; 1990 Oct; 50(20):6497-501. PubMed ID: 2208108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palladium(II) and platinum(II) organometallic complexes with 4,7-dihydro-5-methyl-7-oxo[1,2,4]triazolo[1,5-a]pyrimidine. Antitumor activity of the platinum compounds.
    Ruiz J; Villa MD; Cutillas N; López G; de Haro C; Bautista D; Moreno V; Valencia L
    Inorg Chem; 2008 Jun; 47(11):4490-505. PubMed ID: 18447329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells.
    Martelli L; Di Mario F; Ragazzi E; Apostoli P; Leone R; Perego P; Fumagalli G
    Biochem Pharmacol; 2006 Sep; 72(6):693-700. PubMed ID: 16844093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
    Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
    Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.